GleamWall
中文EN

VXRT Vaxart, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 72444 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.3%
TTM net income YoY157.3%
TTM EPS YoY—
Revenue 3-yr CAGR252.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin16.6%
Net margin16.0%
FCF margin17.6%
EBITDA margin19.3%

Returns

ROE62.4%
ROA16.3%
ROIC (approx.)143.3%
Asset turnover1.02x

Leverage & solvency

Liabilities / assets55.3%
Debt / equity0.00x
Current ratio1.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.13x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.62M$27.18M$39.23M$104.24M$72.41M$39.73M$20.88M$15.19M
R&D expense$22.83M$33.75M$29.41M$45.15M$75.95M$49.73M$30.74M$22.65M
SG&A expense$5.07M$6.60M$4.64M$3.67M$4.28M$4.60M$5.07M$4.02M
Operating income-$17.28M-$13.17M$5.17M$55.42M-$7.81M-$14.60M-$14.94M-$11.49M
Pretax income-$17.38M-$13.46M$5.21M$55.39M-$8.12M-$14.97M-$15.50M-$11.81M
Income tax$312,000$29,000$29,000$344,000$17,000$20,000$95,000$176,000
Net income-$17.69M-$13.49M$5.18M$55.05M-$8.14M-$14.99M-$15.59M-$11.98M
EBITDA-$16.48M-$12.37M$6.30M$57.48M-$6.91M-$13.70M-$12.69M-$9.26M
EPS (basic)-0.07-0.060.02—-0.04-0.07-0.07—
EPS (diluted)——0.02———-0.07—
Weighted avg. shares (diluted)——242.18M———227.92M—
Balance sheet
Cash & equivalents$35.12M$50.93M$50.75M$53.81M$16.88M$20.11M$28.70M$25.23M
Short-term investments$30.43M$13.05M$10.28M$9.99M$11.91M$6.16M$13.24M$26.49M
Receivables$21.03M$11,000$7.14M$14.56M$42.72M$4.28M$1.50M$5.76M
Current assets$126.43M$116.69M$131.70M$136.12M$117.37M$70.38M$62.65M$68.26M
PP&E, net$5.01M$5.50M$4.83M$5.43M$6.06M$6.93M$7.82M$8.71M
Goodwill$4.51M$4.51M$4.51M$4.51M$4.51M$4.51M$4.51M$4.51M
Intangibles$2.28M$2.46M$2.64M$2.83M$3.01M$3.19M$3.38M$3.56M
Total assets$148.18M$165.19M$180.06M$186.08M$208.99M$164.09M$158.56M$166.39M
Current liabilities$73.93M$73.11M$76.84M$86.75M$169.30M$117.88M$98.50M$90.88M
Total liabilities$81.89M$82.81M$85.94M$98.28M$182.23M$131.21M$112.94M$107.46M
Shareholders' equity$66.29M$82.37M$94.12M$87.80M$26.76M$32.88M$45.62M$58.92M
Shares outstanding243.70M242.84M241.41M240.49M228.96M228.91M228.22M227.77M
Cash flow statement
Operating cash flow$1.43M$2.78M-$2.05M$30.66M$2.60M-$15.95M-$9.60M-$7.34M
Capital expenditure$371,000$35,000$448,000$1,000$117,000-$103,000$130,000$44,000
Free cash flow$1.06M$2.74M-$2.50M$30.66M$2.48M-$15.84M-$9.73M-$7.39M
Investing cash flow-$17.66M-$2.72M-$676,000$1.99M-$5.82M$7.23M$13.23M$10.40M
Financing cash flow$411,000$121,000-$338,000$4.28M-$4,000$125,000-$164,000$136,000
Depreciation & amortization$800,000$800,000$1.13M$2.06M$900,000$900,000$2.25M$2.24M
Stock-based compensation$1.19M$1.29M$1.48M$1.72M$2.02M$2.12M$2.46M$2.35M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.